Genetic pathways leading to therapy-related myeloid neoplasms (Mediterr J Hematol Infect Dis. 2011;3(1):e2011019. Epub 2011 May 16.)
Genetic pathways leading to therapy-related myeloid neoplasms.
Stoddart A, McNerney ME, Bartom E, Bergerson R, Young DJ, Qian Z, Wang J, Fernald AA, Davis EM, Larson RA, White KP, Le Beau MM.
SourceUniversity of Chicago, Chicago, IL, USA.
Abstract
Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy. t-MN arises in most cases from a multipotential hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell. The prognosis for patients with t-MN is poor, as current forms of therapy are largely ineffective. Cytogenetic analysis, molecular analysis and gene expression profiling analysis of t-MN has revealed that there are distinct subtypes of the disease; however, our understanding of the genetic basis of t-MN is incomplete. Elucidating the genetic pathways and molecular networks that are perturbed in t-MNs, may facilitate the identification of therapeutic targets that can be exploited for the development of urgently-needed targeted therapies.
Research Papers
- Light-Driven Changes in Energy Metabolism Directly Entrain the Cyanobacterial Circadian Oscillator
- A Vision for a Biomedical Cloud
- Consequences of eukaryotic enhancer architecture for gene expression dynamics, development, and fitness
- Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.
- Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data
- A user's guide to the encyclopedia of DNA elements (ENCODE). (PLoS Biol. 2011 Apr;9(4):e1001046. Epub 2011 Apr 19)